Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Yu Fan

Q2 2024 · 13F-HR

Yu Fanholdings as filed

Filed 2024-08-14 · accession 0000950123-24-008418

$76.5M
Reported value
6
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
156944100CGONCG ONCOLOGY INC$49.8M65.1%1,578,344CommonSOLE
14179K101CRGXCARGO THERAPEUTICS INC$15.0M19.6%912,000CommonSOLE
022307102ALMSALUMIS INC$10.5M13.7%789,618CommonSOLE
14843C105CSTLCASTLE BIOSCIENCES INC$799,9821.05%36,747CommonSOLE
747324101PYXSPYXIS ONCOLOGY INC$229,3930.30%69,303CommonSOLE
786700104SGMTSAGIMET BIOSCIENCES INC$195,5900.26%57,190CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.